Estimated reading time: 4 minutes
Key Takeaways
- Hims & Hers stock experienced a notable surge in late July 2025, with a price increase from about $58.68 to over $60.27, indicating strong investor interest.
- The company is expanding its international telehealth platform, notably in Canada, and diversifying its product offerings, including weight-loss drugs with GLP-1.
- Despite positive price momentum, analyst sentiment remains cautious, with an average 12-month target around $40.73 and a market cap near $14.6 billion.
- Upcoming earnings reports and competitive developments in the weight-loss drug segment are key factors to watch for future performance.
- Hims & Hers exemplifies the evolving telehealth sector with rapid growth, market expansion, and increasing healthcare competition, making it a company to monitor in 2025.
Table of Contents
What’s Happening with Hims Stock?
What Should Investors Watch Next?
What’s Happening with Hims Stock?
Hims & Hers stock saw a significant price rise in late July 2025, rallying from about $58.68 to over $60.27 recently, with intra-day swings topping 10% several days.[1] Volume has surged alongside price increases, signaling strong investor interest and momentum. The stock is currently in a broad but somewhat volatile uptrend and is forecasted to rise around 5% over the next three months with a wide potential price range, reflecting some uncertainty but positive expectations.[1]
Why Is Hims Stock So Active?
Expanding Market Reach: Hims & Hers has been broadening its telehealth platform internationally, including notable progress in Canada, which is boosting its customer base and revenue potential.[4]
Product and Service Growth: The company offers an expanding suite of health and wellness products, including prescription and over-the-counter items, continuing care services, and notably entering the competitive weight-loss market with GLP-1 drugs.[2][3]
Competitive Healthcare Landscape: Recent reports highlight shifting competition in the weight-loss drug segment, with Hims & Hers benefiting from Novo Nordisk’s new challenges, positioning itself as a key aggregator of healthcare demand.[3]
What Do Analysts Say?
Despite the positive price action, consensus analyst sentiment is mixed. Among 11 analysts tracked, the average rating remains “Hold.” The average 12-month price target is around $40.73, implying a decline from the current price and reflecting caution about valuation or execution risks.[2]
Financially, the company commands a sizeable market cap around $14.6 billion, with a strong revenue run-rate ($1.78 billion) but a high price-to-earnings ratio (~96), suggesting growth expectations are priced in but may also warrant scrutiny on earnings sustainability.[2]
What Should Investors Watch Next?
- Earnings Report: Hims is set to announce earnings on August 4, 2025, which could provide clarity on its growth prospects and profitability trajectory.[2]
- Competitive Developments: The unfolding battle over GLP-1 weight-loss drugs and how Hims can capitalize amid rising competition will be critical for future performance.[3]
- Market Volatility: Given the stock’s recent price swings and broad price forecast range, risk management is essential for investors.
Why This Matters
Hims & Hers exemplifies the evolving telehealth and health consumer products sector, marked by direct-to-consumer models, rapid market expansion, and increasing healthcare competition. Its stock surge reflects both excitement about growth opportunities and caution due to inherent uncertainties.
For retail and institutional investors alike, Hims is a company to watch as telehealth gains traction worldwide and healthcare consumerization reshapes traditional delivery models.
FAQ
When will Hims report earnings in 2025?
Hims is set to announce earnings on August 4, 2025, which could shed light on its growth trajectory and financial health.
What is the outlook for Hims stock?
The stock has recently surged but faces cautious analyst projections, with a 12-month target around $40.73. Investors should consider upcoming earnings and industry developments.
What factors are influencing Hims’ growth?
Key factors include international expansion, new product offerings like weight-loss drugs, and competitive dynamics in the healthcare sector, especially regarding GLP-1 drugs.